Compare HAS & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HAS | PODD |
|---|---|---|
| Founded | 1923 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 12.7B |
| IPO Year | 1994 | 2007 |
| Metric | HAS | PODD |
|---|---|---|
| Price | $97.24 | $152.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 21 |
| Target Price | $109.73 | ★ $341.48 |
| AVG Volume (30 Days) | ★ 1.6M | 1.0M |
| Earning Date | 05-20-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 3.48 |
| Revenue | ★ $5,365,900,000.00 | $2,708,100,000.00 |
| Revenue This Year | $5.38 | $24.55 |
| Revenue Next Year | $6.48 | $19.18 |
| P/E Ratio | ★ N/A | $48.03 |
| Revenue Growth | 13.06 | ★ 30.73 |
| 52 Week Low | $61.19 | $158.35 |
| 52 Week High | $106.98 | $354.88 |
| Indicator | HAS | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 57.69 | 21.69 |
| Support Level | $86.85 | N/A |
| Resistance Level | $98.63 | $299.75 |
| Average True Range (ATR) | 3.04 | 8.24 |
| MACD | 0.24 | -2.13 |
| Stochastic Oscillator | 84.27 | 6.40 |
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Peppa Pig, and Magic: The Gathering. The firm acquired EOne in 2019, bolting on popular family properties like Peppa Pig and PJ Masks, and has since divested noncore lines from the tie-up. Furthermore, the addition of Dungeons & Dragons Beyond in 2022 offers the firm access to 19 million digital tabletop players.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.